Project description:This study perfromed RNAseq on two FFPE lung samples from deceased participants from the 1867 RSV vaccine trial and compared these data to age and race matched controls from LungMAP.

2021-10-22 | GSE183435 | GEO

Transcription profiling of lung and bronchial lymph node from mice infected with Respiratory Syncytial Virus (RSV)

Project description:Transcriptional responses in lungs of mice infected with Respiratory Syncytial Virus (RSV) were compared to a control and mock infections

2007-04-17 | E-TABM-221 | biostudies-arrayexpress

Small noncoding RNA Expression Following Respiratory Syncytial Virus or Measles Virus Infection of Neuronal Cells

Project description:In this dataset, we identify microRNAs and other ncRNAs in neuronal (SHSY5Y) cells following a 12h or 24h infection with Respiratory Syncytial Virus (RSV) or Measles virus (MeV) relative to mock treated neuronal cells

2021-09-22 | GSE167724 | GEO

Respiratory syncytial virus induces alternative mRNA processing

Project description:Respiratory syncytial virus induces alternative mRNA processing

| PRJNA704727 | ENA

Multi-organ profiles of C fiber degenerated (KPCF) mice and respiratory syncytial virus (RSV)-infected KPCF mice

Project description:Stimulation of unmyelinated C-fibers is able to initiate host responses. In this study, we established the model of C fiber degenerated (KPCF) mice. KPCF mice were given respiratory syncytial virus (RSV) infection. We aimed to figure out the role of C fibers in RSV infection.

2022-10-11 | GSE215099 | GEO

Blood mRNA profiling to support prognosis of disease severity in respiratory syncytial virus infected infants

Project description:In this study we investigated whether there exists a genomic signature that can accurately predict the course of a respiratory syncytial virus (RSV) infection in hospitalized young infants. We used early blood microarray transcriptome profiles from 39 infants that were followed until recovery and of which the level of disease severity was determined retrospectively. Applying support vector machine learning on age by sex standardized transcriptomic data, an 84 gene signature was identified that discriminated hospitalized infants with eventually less severe RSV infection from infants that suffered from most severe RSV disease.

2016-11-11 | E-MTAB-5195 | biostudies-arrayexpress

Viral N6-methyladenosine upregulates replication and pathogenesis of human respiratory syncytial virus

Project description:N6-methyladenosine (m6A) is the most prevalent internal modification of mRNAs in most eukaryotes. Likewise, viral RNAs may acquire m6A methylation during replication within these cells. Here we show that RNAs of human respiratory syncytial virus (RSV), a medically important non-segmented negative-sense (NNS) RNA virus, are modified by m6A within discreet regions and that these modifications enhance viral replication and pathogenesis. Overexpression of m6A binding proteins significantly enhanced RSV replication and gene expression. Knockdown of m6A methyltransferases decreased viral replication and gene expression whereas knockdown of m6A demethylases had the opposite effect. The G gene contained the most abundant m6A modifications. Recombinant RSV expressing a G gene lacking different m6A sites, resulted in RSVs with various degrees of defects in replication in A549 cells, primary well differentiated human airway epithelial (HAE) cultures, upper and lower respiratory tract of cotton rats, and were also less pathogenic to the lungs of cotton rats. One of the m6A-deficient rgRSVs, rgRSV-G12, was completely attenuated yet retained high immunogenicity in cotton rats. Moreover, a small molecule that inhibits S-adenosyl-L-homocysteine (SAH) hydrolase, thereby reducing the cellular SAH pool and viral RNA m6A, also inhibited RSV replication in HAE cells. Collectively, our results demonstrate viral m6A methylation upregulates RSV replication and pathogenesis and identify viral m6A methylation as a target for rational design of live attenuated vaccine candidates and for novel antiviral therapeutic agents for RSV.

2019-09-10 | GSE125803 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data